- Home
- ETNB
ETNB
89bio Inc.
as 10-07-2025 3:29pm EST
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
| Founded: | 2018 | Country: | United States |
| Employees: | 93 | City: | SAN FRANCISCO |
| Market Cap: | 2.2B | IPO Year: | 2019 |
| Target Price: | $22.31 | AVG Volume (30 days): | 9.5M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.16 - $15.06 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest 89bio Inc. News
ETNB Breaking Stock News: Dive into ETNB Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Assessing 89bio (ETNB) Valuation Following a 60% Share Price Rally
GlobeNewswire
7 days ago
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
Insider Monkey
8 days ago
89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal
GlobeNewswire
4 months ago
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
4 months ago
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
Insider Monkey
5 months ago
Why 89bio, Inc. (ETNB) Is Among the Best Low Priced Biotech Stocks to Buy Now
GlobeNewswire
5 months ago
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
5 months ago
89bio to Participate in Upcoming Investor Conferences
Compare ETNB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ETNB 89bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.